NIH Built a K Award for People Who Do Not Have a Lab Yet. The ACE K32 Opened September 12 and the First Deadline Is October 12.

NIH opened PAR-27-062, the Academic Career Excellence (ACE) Award (K32 — Independent Clinical Trial Not Allowed), on September 12, 2026. The first application due date is October 12, 2026, with recurring cycles thereafter and an expiration date of July 13, 2029.

Five institutes are participating: NCI, NIAID, NIBIB, NIDCR, and NINDS. That breadth is unusual for a K mechanism and it is the first thing worth noticing — this is not a single-institute pilot, it is a coordinated attempt to put a career-development instrument at a stage of the pipeline where NIH has historically had almost nothing to offer.

The gap this fills

Walk the NIH career-development ladder as it actually exists for a biomedical researcher:

• F31 — predoctoral fellowship, while you are a graduate student.
• F32 — postdoctoral fellowship, individual research training.
• K99/R00 — the "pathway to independence" award, which requires no more than four years of postdoctoral experience and is explicitly aimed at people preparing to leave the postdoc for a faculty position.
• K08 / K23 / K01 — mentored career development, generally for people who already hold a faculty or faculty-equivalent appointment.

The hole sits in the first two years of the postdoc. You have a PhD, you have joined a lab, you are not yet competitive for K99 (which rewards a substantial independent body of postdoctoral work), and you are years away from the K08/K23 tier. Your salary is a line item on your mentor's R01. Your research direction is, functionally, your mentor's research direction.

The ACE K32 targets exactly that window. It supports up to three years early in the postdoctoral training period and is designed to "expand the scientific research experience of the candidate from their predoctoral training" — meaning the point is a genuine pivot, not a continuation.

What the award actually pays

The $80,000 salary cap deserves a moment. NIH postdoctoral stipend levels under the NRSA scale start meaningfully below that figure, and many institutions pay their postdocs close to the NRSA floor. An $80,000 institutional base salary plus fringe, carried for three years and not charged to a mentor's R01, is a material shift in the economics of a postdoc position — for the postdoc and for the mentor's budget.

The $30,000 annual research development allocation is the part that changes behavior. It covers supplies, equipment, training, travel, and statistical services. Ninety thousand dollars of discretionary research money over three years does not fund an independent lab, but it funds something that matters more at this stage: the ability to pursue a question your mentor's grant does not cover. That is the mechanism by which a postdoc accumulates preliminary data that belongs to them rather than to the R01 they are paid from — which is, in turn, the precondition for a competitive K99 or a faculty application.

The 8 percent F&A rate is standard for K awards and worth flagging for research administrators building the budget. This is not a negotiated-rate award. Institutions evaluating whether to support ACE applicants should understand they are absorbing most of the indirect burden, which is exactly why the funding opportunity asks the institution to document "strong research career development infrastructure." NIH is explicitly checking whether the institution is a willing partner in an arrangement that is not financially advantageous to it.

The eligibility window is the competition

Everything else in this announcement is negotiable through a well-written application. The timing rule is not.

Candidates must submit their application up to one year prior to beginning their postdoctoral position, or no more than two years after their postdoctoral training begins — resubmissions included.

Parse the parenthetical, because it is doing enormous work. Resubmissions count against the same window. If you submit at month 20 of your postdoc, get a fundable-but-unfunded score, and plan to resubmit, your A1 has to land inside the same two-year boundary. A standard NIH review cycle plus revision time is roughly eight months. Submitting late in the window means you effectively get one shot.

The strategic implication is unambiguous: submit early in the window, not late. A candidate at month six with less preliminary data but two clean resubmission opportunities is in a materially stronger position than a candidate at month 22 with a better draft and no runway. The announcement also explicitly states that preliminary data is not required, and that the emphasis falls on "innovative ideas and comprehensive mentoring plans." NIH has told you directly that it is not scoring you on accumulated results. Believe it and submit early.

The forward-looking half of the window — up to one year before starting the postdoc — is the underused one. A final-year graduate student who has identified their postdoctoral lab can apply before they arrive. That candidate walks into the new position with independent salary support in hand, which changes the negotiation about what they work on before it starts.

The other eligibility bars

Citizenship: U.S. citizen or lawful permanent resident by the time of award. This is a hard bar and it excludes a substantial share of the U.S. postdoctoral workforce. International postdocs should look at institutional K12 programs, foundation fellowships, and the F32 pathway instead.

Prior support: candidates cannot be current or former PIs on an R01, P01, P50, or a major K award, and cannot have received an F99/K00. The F99/K00 exclusion is the pointed one — NIH is deliberately not stacking two transition mechanisms on the same person. If you hold a K00, this award is not available to you; that is by design, because the K00 already funds your postdoc.

Effort: 75 percent minimum, nine person-months annually. This is enforced and it constrains candidates carrying clinical service obligations. A clinician-scientist with a 50 percent clinical load cannot make this work without a departmental commitment to buy the time down.

Institutions: nonprofit, for-profit, and government organizations are all eligible. Foreign organizations are ineligible and no foreign subawards are permitted. Note that for-profit eligibility is genuinely unusual for a mentored K and opens the mechanism to postdocs in industry research settings with a qualifying mentor — a small but real expansion.

What it replaces, and what changed

The ACE K32 descends from the NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence Award, forecast under NOT-CA-25-019. The CURE program was NCI's long-running structure for supporting cancer researchers from backgrounds underrepresented in biomedical science, running continuously from the predoctoral stage through early faculty appointments.

The award that actually published is not the CURE-branded one. PAR-27-062 is titled simply "Academic Career Excellence (ACE) Award," it is open to all eligible candidates rather than scoped to a defined population, and four institutes beyond NCI have joined it. This matches the broader 2025–2026 restructuring across NIH career-development and training portfolios, in which population-targeted mechanisms have been reissued as open competitions.

Two practical consequences follow.

First, the applicant pool is much larger than CURE's was. Anyone modeling their odds on historical CURE ACE success rates is modeling the wrong denominator.

Second, the framing of the application has to change. Under CURE, a candidate's background was a scored and explicitly relevant element of the narrative. Under PAR-27-062, the scored criteria are candidate qualifications and potential, the career development and mentoring plan, research plan rigor and feasibility, mentor qualifications and commitment, and institutional environment. Applicants recycling a CURE-era draft should audit it against those five criteria specifically, and should assume that what carried weight before will not carry the same weight now.

The clinical trial boundary

The title says "Independent Clinical Trial Not Allowed," and the announcement draws the line precisely: the candidate may not lead an independent clinical trial, but may gain clinical trial experience under the supervision of a mentor or co-mentor.

This is a meaningful allowance for translational and clinical candidates. You can participate substantively in a trial your mentor runs and describe that participation as career development. You cannot propose a trial of your own. A separate ACE K32 variant with clinical trial required has been forecast, which suggests NIH intends to cover both cases — but as of the October 12 cycle, PAR-27-062 is the one that is open.

Building the application

The five scored criteria are ordered in a way that tells you where the weight sits. Candidate and mentor dominate. In practice:

The mentor is half the application. NIH requires an active investigator in the proposed research area with demonstrated mentoring experience at the candidate's career stage and documented research support and facilities. A brilliant PI who has never trained a postdoc is a liability here. A mid-career PI with a visible record of launching postdocs into faculty positions is an asset that partially substitutes for the candidate's own thin record. Choose accordingly, and if a co-mentor fills a gap — statistical, clinical, methodological — name them and give them defined responsibilities.

The pivot has to be legible. The program exists to expand the candidate's experience beyond predoctoral training. Reviewers will look for the distance between the dissertation and the proposal. A postdoc continuing their PhD work in a new building is the weakest version of this application. A candidate bringing a computational skill set into a wet-lab disease problem, or the reverse, is the strongest.

The career development plan is not boilerplate. With no preliminary data required, the development plan carries scoring weight that would otherwise go to results. Coursework, formal training, defined milestones with dates, a plan for the transition out of the postdoc — specificity is the whole game.

Get the institutional letter early. The announcement requires the institution to document a strong research career development infrastructure. At 8 percent F&A and a $80,000 salary line, that letter is a genuine commitment, and offices of sponsored research move slowly on commitments they are not accustomed to making.

With a first cycle on October 12, 2026 and recurring quarterly cycles through July 2029, there is a rational case for skipping the first deadline in favor of a stronger package on the next one — unless you are close to the two-year boundary. For candidates in months eighteen through twenty-four of a postdoc, October 12 may be the only real opportunity this mechanism will offer. Check your own clock before you decide.